Coronary Artery Disease
Conditions
Interventions
Duration: from 5 - 10 days before PCI to the day of PCI Drug: rosuvastatin 2.5 mg Method: oral administration once a day
Duration: from 5 - 10 days before PCI to the day of PCI Drug: rosuvastatin 1
Sponsors
Nippon Medical School
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with coronary aretery disease undergoing PCI 2. dyslipidemia (T-CHO=>220 mg/dl, TG=>150 mg/dl, HDL-CHO<40 mg/dl, or LDL-CHO=>100mg/dl, or already treated with statin) 3. Patients who agree to participate in this study.
Exclusion criteria
Exclusion criteria: 1. Patients with severe renal disease (sCR=>3.0, urine protein +++ urine OB +++) or liver disease (AST>100IU/l, ALT>100IU/l, T-bil>3.0mg/dl, PT<60%, albumin<2.8g/dl) 2. ACS patients who need to receive emergency revascularization 3. Patients with no-PCI indication lesion such as LMT 4. in-stent or para-stent restenosis 5. Patients who cannot take statin 6. malignancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| a) PCI related cardiac complication b) elevation of the following cardiac markers 1) troponin T 2) N-terminal pro brain natriuretic peptide 3) CPK, CPK-MB C) EKG change after PCI D) no reflow or slow flow after PCI | — |
Secondary
| Measure | Time frame |
|---|---|
| a) any adverse events related to rosuvastatin b) no reflow or slow reflow during PCI c) PCI related non-cardiac complication d) IVUS findings before PCI e) Cardiac events or death after 3-year follow-up period | — |
Countries
Japan
Contacts
Public ContactHitoshi Takano
nippon Medical School Department of Medicine
Outcome results
None listed